查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863554

心臟就地检验市场按产品类型、最终用户、分销管道、检测模式、技术和应用划分－2025-2032年全球预测

Cardiac Point of Care Testing Market by Product Type, End User, Distribution Channel, Test Mode, Technology, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，心臟就地检验市场规模将达到 259.5 亿美元，复合年增长率为 13.55%。

关键市场统计数据
基准年 2024 93.8亿美元
预计年份：2025年 106.6亿美元
预测年份 2032 259.5亿美元
复合年增长率 (%) 13.55%

本文阐述了加速诊断应对力和分散式心臟检测为何正在重塑临床路径和市场优先事项的策略框架。

心臟就地检验已成为急慢性心血管疾病治疗路径中的关键转折点，它使临床医生能够在患者家门口快速做出决策，并将诊断范围扩展到传统检查室之外。近期技术进步缩短了检测时间，提高了分析灵敏度，而医疗保健趋势正在推动急诊诊所、门诊中心、居家医疗机构和医院检查室对分散式检查的需求。这些趋势正在重塑临床医生对胸痛进行分诊、监测心臟衰竭和评估心血管风险的方式，快速的诊断结果将带来更及时的干预措施和更精简的诊疗路径。

生物标记灵敏度的提高、设备的微型化以及医疗服务改革正在共同重塑心臟诊断和临床工作流程。

在技​​术创新、临床实践发展和医疗服务改革的共同推动下，心臟就地检验领域正经历变革性的转变。高灵敏度的生物标记检测延长了心肌损伤和心臟衰竭的诊断窗口期，促使人们重新评估分诊通讯协定，并缩短急诊和门诊患者的治疗时间。同时，生物感测器小型化和检测化学技术的进步使得在中心检查室之外也能获得可靠的定量结果，从而支持转向分散式、以患者为中心的诊断模式。

检验2025年关税调整对营运和商业的影响，以及这些调整将如何影响供应链韧性、采购和定价策略。

2025年生效的累积关税为心臟就地检验生态系统带来了新的商业性和营运复杂性。关税导致进口零件、试剂原料和成品诊断设备的成本压力，迫使製造商和经销商重新评估筹资策略和供应链结构。为了降低贸易政策波动带来的风险，一些机构正在加快供应商多元化，包括优先选择低关税地区的合作伙伴，并寻求近岸外包方案。这些策略因应措施对采购产生直接影响，并可能影响各通路的产品定价和利润率趋势。

透过深入的細項分析，将产品类型、最终用户需求、通路、测试模式、技术和临床应用连结起来，从而解锁有针对性的策略重点。

细分市场分析揭示了临床需求、技术契合度和分销动态之间的交集，从而在心臟就地检验市场中创造了差异化的机会。按产品类型划分，市场涵盖脑钠肽（BNP）、C反应蛋白、肌酸激酶MB（CK MB）、肌红蛋白和肌钙蛋白，并进一步区分了BNP与N端脑钠肽前体（NT-proBNP）、C反应蛋白与高敏和标准方法，以及肌钙蛋白从肌钙蛋白I到肌钙蛋白T。终端使用者细分揭示了门诊中心、急诊诊所、居家医疗服务和医院检查室在采用模式上的差异，表明每个机构都有其独特的工作流程要求、人员能力和采购行为。分销管道包括医院药房、线上管道（包括B2B入口网站和D2C服务）以及零售药房，每个管道都有不同的利润率预期和客户参与模式。

医疗保健基础设施、监管要求和製造生态系统方面的区域差异会影响产品的采用路径和策略性市场推广方式。

区域趋势对即时心臟检测 (POCT) 的应用路径、监管要求和供应链决策有重大影响。在美洲，急诊对快速分流的需求以及日益增长的居家医疗倡议（这些计划倾向于使用携带式诊断设备）正在推动临床应用，但公立和私立医疗系统之间的采购週期和报销机制存在显着差异。欧洲、中东和非洲地区呈现多元化的格局，监管协调工作与市场分散并存，导致设备和检测套组的应用路径各不相同。虽然集中式系统在某些地区仍然占据主导地位，但其他市场正在快速采用分散式检查，这通常受到公共卫生优先事项和投资能力的影响。亚太地区拥有先进的城市医疗保健系统和完善的检测网络，而新兴经济体正在迅速扩展基层医疗基础设施。该地区的製造能力和供应商生态系统在全球供应链中也发挥核心作用，影响采购决策和定价趋势。

竞争与合作趋势凸显了平台现有企业和创新者如何利用分销、连接和证据生成来确保可持续的市场地位。

就地检验领域的竞争格局既有成熟的诊断设备製造商，也有专注于超灵敏生物标誌物、以用户为中心的设备设计和整合数位生态系统等细分领域的敏捷型新兴企业。大型平台公司往往利用其广泛的分销网络、完善的监管体系和跨产品组合的协同效应来扩大应用规模，而新兴参与企业则专注于平台灵活性、低成本製造或能够实现快速迭代开发的新型生物感测器技术。

为製造商、经销商和医疗系统制定切实可行的高优先级行动指南，以加速产品推广应用、增强韧性并与临床优先事项保持一致。

产业领导者若想加速推广应用并建立稳健的业务，应优先考虑兼顾临床可靠性、供应链灵活性和终端用户体验的实用策略。首先，应投资于临床证据，以证明就地检验与病患诊疗路径的可衡量改善（例如，缩短诊断时间、避免不必要的住院治疗）之间的关联，并确保这些证据涵盖各种终端使用者环境，包括门诊中心、急诊诊所、居家医疗机构和医院检查室。其次，应透过组装替代采购管道、尽可能将组装环节外包以及签订包含价格保护条款的长期供应协议，实现供应链多元化，从而降低关税和贸易政策的影响。

采用综合临床医师访谈、技术性能评估、监管审查和通路经济学的调查方法，建构了严谨的多面向分析。

该研究的综合分析基于多学科调查方法，结合了临床、技术、监管和商业性观点。主要资讯来源包括对急诊医学和心臟病学临床医生、门诊和医院采购负责人以及诊断设备製造商和分销合作伙伴的高管进行的结构化访谈，以深入了解推广应用障碍和工作流程优先事项。次要资讯来源包括对同侪审查的科学文献、监管指导文件以及近期发布的监管文件（详细说明医疗设备审批、测试检验和互通性要求）的系统性回顾。此外，还进行了一项技术评估，将包括生物感测器、免疫检测和横向流动化验在内的分析方法与临床性能标准和可用性指标进行配对。

本文简要概述了相关人员为充分发挥分散式心臟诊断的潜力而必须解决的临床、技术和操作要求。

总之，心臟就地检验在现代心血管诊疗流程中发挥着至关重要的作用，能够加快急诊、门诊和家庭环境中的临床决策。高灵敏度检测、生物感测器创新以及数位化整合技术的进步正在拓展其实际应用范围，而报销和法规环境的变化则影响其应用轨迹。然而，近期贸易政策的波动凸显了供应链韧性、成本透明度和适应性筹资策略对于维持竞争优势和确保诊断用品稳定供应的重要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用携带式照护现场分析仪进行高灵敏度肌钙蛋白检测法，快速诊断心肌梗塞
  • 智慧型手机连接的心电图设备可实现远端心律不整监测和心臟事件检测。
  • 开发一种多重生物标记平台，能够在紧急医疗环境中同时检测心臟功能生物标记。
  • 将人工智慧演算法整合到就地检验设备中，以提高急性冠状动脉症候群诊断的准确性
  • 实施云端基础的资料管理系统，实现医疗保健网路内心臟检测结果的即时共用
  • 监管核准趋势促进新型微流体心臟照护现场诊断晶片进入市场
  • 加强设备製造商与远端医疗提供者之间的合作，以扩大农村地区心臟检测的覆盖范围

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型就地检验市场

  • BNP
    • BNP
    • Nt ProBNP
  • C反应蛋白
    • 高敏C反应蛋白
    • 标准C反应蛋白
  • CK MB
  • 肌红蛋白
  • 肌钙蛋白
    • 肌钙蛋白 I
    • 肌钙蛋白T

9. 按最终用户就地检验市场

  • 门诊治疗中心
  • 急诊诊所
  • 居家医疗
  • 医院检查室

第十章 按分销管道就地检验市场

  • 医院药房
  • 线上管道
    • B2B入口网站
    • D2C
  • 零售药房

第十一章：依检测模式就地检验市场

  • 定性
  • 定量

12. 依技术就地检验市场

  • 生物感测器
    • 电化学感测器
    • 光学感测器
  • 免疫检测
    • 化学冷光免疫检测
    • 酵素免疫分析法
  • 横向流动化验

第十三章：按应用就地检验市场

  • 心肌梗塞的诊断
  • 心臟衰竭监测
  • 风险评估

14. 各地区心臟就地检验市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 按群体就地检验市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：各国心臟就地检验市场概况

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • F. Hoffmann-La Roche AG
    • Siemens Healthineers AG
    • Quidel Corporation
    • Radiometer Medical ApS
    • Nova Biomedical Corporation
    • Sekisui Diagnostics, LLC
    • Accriva Diagnostics, Inc
    • Randox Laboratories Ltd
Product Code: MRR-3F5063247F53

The Cardiac Point of Care Testing Market is projected to grow by USD 25.95 billion at a CAGR of 13.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.38 billion
Estimated Year [2025] USD 10.66 billion
Forecast Year [2032] USD 25.95 billion
CAGR (%) 13.55%

A strategic framing of why accelerated diagnostic responsiveness and decentralized cardiac testing are reshaping clinical pathways and market priorities

Cardiac point-of-care testing has emerged as a critical inflection point for acute and chronic cardiovascular care pathways, enabling faster clinical decision-making at the patient's side and expanding diagnostic reach beyond traditional laboratory settings. Recent technological advances have reduced assay run-times and improved analytical sensitivity, while healthcare delivery trends have driven demand for decentralized testing in emergency clinics, ambulatory care centers, home healthcare settings, and hospital laboratories. These dynamics are reshaping how clinicians triage chest pain, monitor heart failure, and stratify cardiovascular risk, with faster diagnostic results translating into more timely interventions and streamlined care pathways.

Concurrently, improvements in immunoassay platforms, lateral flow devices, and biosensor technologies are converging with digital integration and connectivity solutions, enabling more actionable data flows and remote monitoring capabilities. This shift is accompanied by evolving reimbursement and regulatory frameworks that are increasingly accommodating point-of-care modalities, albeit with variability across regions. Therefore, stakeholders-ranging from device manufacturers and distributors to hospital procurement teams and policy makers-must weigh clinical utility, workflow integration, and cost structures when evaluating adoption strategies.

This introduction frames the subsequent analysis by emphasizing clinical impact, technological progress, and operational considerations that together define strategic opportunities and risks in cardiac point-of-care testing.

How advances in biomarker sensitivity, device miniaturization, and care delivery reforms are jointly redefining cardiac diagnostics and clinical workflows

The landscape of cardiac point-of-care testing is undergoing transformative shifts driven by a combination of technological innovation, clinical practice evolution, and healthcare delivery reform. High-sensitivity biomarker assays have extended the diagnostic window for myocardial injury and heart failure, prompting emergency and ambulatory settings to re-evaluate triage protocols and reduce time-to-treatment. At the same time, biosensor miniaturization and improvements in assay chemistry have made reliable quantitative results feasible outside central laboratories, supporting a broader shift toward decentralized, patient-centric diagnostics.

These technology-driven advances are intersecting with shifting care models, where hospital-at-home initiatives, urgent care expansions, and remote monitoring programs are increasing demand for portable, rapid testing. Payment models that reward value-based outcomes and shorter hospital stays further incentivize adoption of point-of-care solutions that can demonstrably reduce length of stay and improve therapeutic targeting. In parallel, digital health integration and interoperability standards are creating expectations for secure data exchange and seamless inclusion of point-of-care results into electronic health records and clinical decision support systems.

Finally, competitive dynamics are changing as established diagnostics companies invest in connectivity and user-experience design, while agile medtech entrants focus on platform flexibility and cost-effective manufacturing. Collectively, these shifts are redefining where and how cardiac biomarkers are measured, how results influence care, and which capabilities will determine market leadership in the near term.

Examining the operational and commercial consequences of 2025 tariff changes and how they compel supply chain resilience, sourcing shifts, and pricing strategies

The introduction of cumulative tariff measures in 2025 has created a new layer of commercial and operational complexity for the cardiac point-of-care testing ecosystem. Tariff-driven cost pressures on imported components, reagent raw materials, and finished diagnostic devices have prompted manufacturers and distributors to reassess sourcing strategies and supply chain architectures. Some organizations have accelerated supplier diversification efforts, prioritizing partners in lower-tariff jurisdictions or pursuing nearshoring options to mitigate exposure to trade policy volatility. These strategic responses have immediate procurement implications and may influence product pricing and margin dynamics across distribution channels.

In practice, increased import costs have been met with a range of adaptations, including longer-term supplier contracts with price-protection clauses, localized assembly to avoid duties on finished goods, and redesigns that reduce dependence on tariff-affected materials. For end users, particularly smaller ambulatory centers and retail pharmacy channels, the pass-through of higher unit costs can constrain adoption momentum unless offset by demonstrable clinical and operational value. Payers and health systems are responding by scrutinizing total cost of care impacts, requiring clearer evidence that point-of-care testing shortens workflows or avoids downstream expenses.

Regulatory and customs processing delays associated with tariff implementation have also highlighted the need for robust inventory planning and buffer strategies. Overall, the tariff environment has elevated supply chain resilience and cost transparency as strategic priorities for manufacturers, distributors, and health system purchasers alike.

Detailed segmentation analysis connecting product categories, end-user requirements, distribution routes, test modes, technologies, and clinical applications to unlock targeted strategic priorities

A granular segmentation analysis reveals where clinical demand, technology fit, and distribution dynamics intersect to create differentiated opportunities across the cardiac point-of-care testing landscape. Product type segmentation encompasses BNP, C Reactive Protein, CK MB, Myoglobin, and Troponin, with further granularity for BNP split into BNP and Nt ProBNP, C Reactive Protein divided into High Sensitivity and Standard assays, and Troponin distinguished between Troponin I and Troponin T. End user segmentation highlights distinct adoption patterns across ambulatory care centers, emergency clinics, home healthcare services, and hospital laboratories, each presenting unique workflow requirements, staffing competencies, and purchasing behaviours. Distribution channels reflect hospital pharmacies, online channels-including Business To Business portals and Direct To Consumer offerings-and retail pharmacies, each channel imposing different margin expectations and customer engagement models.

Test mode segmentation bifurcates the market into qualitative and quantitative modalities, a distinction that maps closely to clinical intent and regulatory scrutiny, while technology segmentation identifies biosensor, immunoassay, and lateral flow assay approaches, with biosensors further categorized into electrochemical and optical sensors and immunoassays differentiated into chemiluminescence immunoassay and enzyme linked immunosorbent assay formats. Application-based segmentation captures the primary clinical use cases of diagnosis of myocardial infarction, heart failure monitoring, and risk assessment, which dictate performance thresholds and integration needs.

Understanding these interlocking segments allows stakeholders to prioritize product development and go-to-market strategies that align analytic performance with user setting, distribution economics, and clinical value propositions, ensuring that innovations address the most pressing unmet needs across care settings.

How regional differences in healthcare infrastructure, regulatory expectations, and manufacturing ecosystems shape adoption pathways and strategic market entry approaches

Regional dynamics exert a material influence on adoption pathways, regulatory expectations, and supply chain decisions within cardiac point-of-care testing. In the Americas, clinical adoption is driven by emergency department demand for rapid triage and by expanding home-based care initiatives that favour portable diagnostics, while procurement cycles and reimbursement mechanisms vary widely between public and private systems. Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with market fragmentation, leading to differentiated pathways for devices and assays; in some areas, centralized systems remain dominant, whereas other markets show rapid uptake of decentralised testing, often influenced by public health priorities and investment capacity. Asia-Pacific displays a mix of advanced urban healthcare systems with sophisticated laboratory networks and rapidly expanding primary care infrastructures in emerging economies; this region's manufacturing capabilities and supplier ecosystems also play a central role in global supply chains, affecting sourcing decisions and price dynamics.

Each region imposes distinct requirements for clinical validation, quality systems, and distribution partnerships. For manufacturers and distributors, tailoring market entry strategies to these regional specifics-balancing regulatory timelines, channel selection, and local partnerships-will drive market traction. For healthcare providers and payers, regional context determines how point-of-care testing is prioritized within broader cardiovascular care initiatives and how value is assessed against competing clinical investments.

Competitive and partnership dynamics highlighting how platform incumbents and innovators leverage distribution, connectivity, and evidence generation to secure durable market positions

Competitive dynamics in cardiac point-of-care testing are shaped by a mix of established diagnostics manufacturers and agile innovators focusing on niche capabilities such as ultra-sensitive biomarkers, user-centric device design, and integrated digital ecosystems. Large-platform companies often leverage broad distribution networks, established regulatory footprints, and cross-portfolio synergies to scale introductions, while emerging entrants concentrate on platform flexibility, lower-cost manufacturing, or novel biosensor technologies that can be rapidly iterated.

Partnerships and strategic alliances are increasingly common as device developers seek to integrate assay expertise with connectivity providers and sample-to-result automation specialists. This collaborative approach accelerates time-to-market for features that matter to clinicians, such as real-time data transmission to electronic health records and decision-support compatibility. In addition, strategic licensing and OEM arrangements enable companies with strong commercial channels to offer complementary assays under co-branded or private-label models, expanding reach without duplicative infrastructure investments.

From a procurement perspective, health systems prioritize vendors that can demonstrate consistent supply, regulatory compliance, and clear pathways for technical support and training. Companies that invest in post-sales support models, local technical presence, and outcome-oriented evidence generation are best positioned to win durable contracts and to support broader clinical adoption across care settings.

Practical and prioritized actions for manufacturers, distributors, and health systems to accelerate adoption, enhance resilience, and align offerings with clinical priorities

Industry leaders seeking to accelerate adoption and build resilient operations should prioritize a set of actionable strategies that balance clinical credibility, supply chain agility, and end-user experience. First, invest in clinical evidence that links point-of-care testing to measurable improvements in patient pathways, such as reduced time-to-decision or avoidance of unnecessary admissions, and ensure that this evidence addresses different end-user contexts including ambulatory centers, emergency clinics, home healthcare, and hospital laboratories. Second, diversify supply chains to mitigate tariff and trade-policy exposure by developing alternate sourcing options, nearshoring assembly where feasible, and negotiating longer-term supply agreements with price protection.

Third, design product portfolios and distribution approaches tailored to channel economics; hospital pharmacies, online channels including B2B portals and direct-to-consumer routes, and retail pharmacies each require distinct pricing, packaging, and service propositions. Fourth, prioritize interoperability and digital integration so that point-of-care results feed seamlessly into clinical workflows and electronic records, thereby increasing clinical utility and adoption. Fifth, adopt a segmented go-to-market strategy that aligns technologies-whether biosensors, immunoassays, or lateral flow formats-with the specific performance requirements of applications such as myocardial infarction diagnosis, heart failure monitoring, and risk assessment.

By combining robust clinical evidence, supply chain resilience, channel-specific commercial design, digital enablement, and targeted segmentation, industry leaders can create defensible positions and accelerate sustainable uptake of cardiac point-of-care testing solutions.

Methodological approach integrating clinician interviews, technical performance assessments, regulatory reviews, and channel economics to build a rigorous multi-perspective analysis

This research synthesis draws on a multidisciplinary methodology designed to integrate clinical, technological, regulatory, and commercial perspectives. Primary inputs included structured interviews with clinicians in emergency medicine and cardiology, procurement professionals across ambulatory and hospital settings, and executives from diagnostic companies and distribution partners, providing qualitative insight into adoption barriers and workflow priorities. Secondary inputs comprised a systematic review of peer-reviewed scientific literature, regulatory guidance documents, and recent public filings that detail device clearances, assay validations, and interoperability requirements. Additionally, technology assessments were conducted to compare analytical approaches such as biosensors, immunoassays, and lateral flow assays against clinical performance criteria and usability metrics.

Analytical frameworks incorporated segmentation mapping to relate product types and technologies to end-user needs and distribution economics, along with scenario analysis to evaluate operational responses to external pressures such as tariff changes. Care was taken to ensure source triangulation, cross-validating claims from interviews with published validation studies and regulatory documentation. Limitations of the methodology include variable transparency in proprietary supplier cost structures and the evolving nature of trade policy and reimbursement pathways, which may influence implementation timelines. Nonetheless, the approach provides a rigorous basis for strategic decision-making by combining clinician perspectives, technical performance evaluation, and commercial channel analysis.

A concise synthesis of clinical, technological, and operational imperatives that stakeholders must align to realize the full potential of decentralized cardiac diagnostics

In conclusion, cardiac point-of-care testing occupies a pivotal role in modern cardiovascular care pathways, offering the potential to accelerate clinical decision-making across emergency, ambulatory, and home-based settings. The convergence of high-sensitivity assays, biosensor innovations, and improved digital integration is expanding the range of viable use cases, while evolving reimbursement and regulatory contexts are shaping adoption trajectories. However, recent trade-policy shifts underline the importance of supply chain resilience, cost transparency, and adaptive sourcing strategies to maintain competitive positioning and ensure consistent access to diagnostic supplies.

For stakeholders, the imperative is clear: align product performance with specific clinical workflows, demonstrate measurable impacts on patient management, and design distribution and support models that reflect the economic realities of each end-user segment. Companies that combine robust clinical evidence, flexible manufacturing and sourcing approaches, and strong post-sales support will be best positioned to convert technical promise into sustained clinical and commercial success. Moving forward, continued collaboration among manufacturers, clinicians, payers, and regulators will be essential to realize the full potential of decentralized cardiac diagnostics while maintaining quality, affordability, and equitable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of high-sensitivity troponin assays in handheld point of care analyzers for faster myocardial infarction diagnosis
  • 5.2. Emergence of smartphone-connected electrocardiogram devices enabling remote arrhythmia monitoring and cardiac event detection
  • 5.3. Development of multiplexed biomarker platforms for simultaneous detection of cardiac biomarkers in emergency settings
  • 5.4. Integration of artificial intelligence algorithms in point of care testing devices to improve diagnostic accuracy for acute coronary syndromes
  • 5.5. Implementation of cloud-based data management systems for real-time sharing of cardiac test results across healthcare networks
  • 5.6. Regulatory approval shifts driving market entry of novel microfluidic cardiac point of care diagnostic chips
  • 5.7. Increasing partnerships between device manufacturers and telehealth providers to expand cardiac testing accessibility in rural areas

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Point of Care Testing Market, by Product Type

  • 8.1. BNP
    • 8.1.1. BNP
    • 8.1.2. Nt ProBNP
  • 8.2. C Reactive Protein
    • 8.2.1. High Sensitivity C Reactive Protein
    • 8.2.2. Standard C Reactive Protein
  • 8.3. CK MB
  • 8.4. Myoglobin
  • 8.5. Troponin
    • 8.5.1. Troponin I
    • 8.5.2. Troponin T

9. Cardiac Point of Care Testing Market, by End User

  • 9.1. Ambulatory Care Centers
  • 9.2. Emergency Clinics
  • 9.3. Home Healthcare
  • 9.4. Hospital Laboratories

10. Cardiac Point of Care Testing Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Channels
    • 10.2.1. Business To Business Portals
    • 10.2.2. Direct To Consumer
  • 10.3. Retail Pharmacies

11. Cardiac Point of Care Testing Market, by Test Mode

  • 11.1. Qualitative
  • 11.2. Quantitative

12. Cardiac Point of Care Testing Market, by Technology

  • 12.1. Biosensor
    • 12.1.1. Electrochemical Sensor
    • 12.1.2. Optical Sensor
  • 12.2. Immunoassay
    • 12.2.1. Chemiluminescence Immunoassay
    • 12.2.2. Enzyme Linked Immunosorbent Assay
  • 12.3. Lateral Flow Assay

13. Cardiac Point of Care Testing Market, by Application

  • 13.1. Diagnosis Of Myocardial Infarction
  • 13.2. Heart Failure Monitoring
  • 13.3. Risk Assessment

14. Cardiac Point of Care Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cardiac Point of Care Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cardiac Point of Care Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. F. Hoffmann-La Roche AG
    • 17.3.3. Siemens Healthineers AG
    • 17.3.4. Quidel Corporation
    • 17.3.5. Radiometer Medical ApS
    • 17.3.6. Nova Biomedical Corporation
    • 17.3.7. Sekisui Diagnostics, LLC
    • 17.3.8. Accriva Diagnostics, Inc
    • 17.3.9. Randox Laboratories Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIAC POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (U